Adlai Nortye Biopharma Co., Ltd.

ANL · Nasdaq · Singapore

Share price · ANL

$8.74-5.42 (-38.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 455K (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ANL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Oct 2026+11.1%
  2. 13 Oct 2026-17.3%

    Nothing announced by ANL that day or the session before.

  3. 8 Oct 2026+10.4%
  4. 15 Jul 2026+15.5%
  5. 29 Apr 2026+15.8%

    Nothing announced by ANL that day or the session before.

  6. 30 Jan 2026+62.8%
  7. 29 Jan 2026+88.2%
  8. 26 Jan 2026+21.7%

    Nothing announced by ANL that day or the session before.

  9. 23 Jan 2026+28.9%

    Nothing announced by ANL that day or the session before.

  10. 30 Dec 2025-17.2%

Share of unusual movement by asset

For each asset, the share of ANL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—7%
Sessions with no dated event—93%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
EP4Small molecule
Non-Small Cell Lung CancerColorectal Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 June 2025Topline resultBuparlisibPhase 3 BURAN (NCT04338399) of buparlisib plus paclitaxel did not meet its primary endpoint of overall survival
Adlai Nortye · Source ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$5.0M$45M$61M$13M-$52M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$46M$58M$91M$26M-$57M operating cash flowreport ↗
2022-FY—$54M$43M$15M-$43M operating cash flowreport ↗
2021-FY$46M$42M$64M$14M-$3.0M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($411K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30Ji Ping · directorOpen-market sale5,000$16.03$80KForm 4
2026-09-30Ji Ping · directorOpen-market sale5,000$15.95$80KForm 4
2026-09-29Ji Ping · directorOpen-market sale214$15.77$3KForm 4
2026-09-22Ji Ping · directorOpen-market sale5,000$16.63$83KForm 4
2026-08-26Ye Xiaofeng · CFOOpen-market sale5,667$14.25$81KForm 4
2026-08-24Ye Xiaofeng · CFOOpen-market sale6,000$13.98$84KForm 4
2026-06-10Ji Ping · directorOther (see filing)136,667——Form 4
2026-05-13LU YANG · director, CEO, 10% ownerOpen-market sale10$13.18$132Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 11.6M shares ($79.5M, 29.0% of shares outstanding).

#InstitutionSharesValue
1Venrock Adviser, LLC3,212,731$22.2M
2Cormorant Asset Management, LP2,897,857$20.1M
3Squadron Capital Management LLC1,265,231$8.8M
4Balyasny Asset Management L.P.877,846$6.1M
5MILLENNIUM MANAGEMENT LLC681,775$4.7M
6Casdin Capital, LLC538,461$3.7M
7ADAGE CAPITAL PARTNERS GP, L.L.C.538,461$3.7M
8SUPERSTRING CAPITAL MANAGEMENT LP414,852$2.9M
9Woodline Partners LP209,259$1.4M
10Affinity Asset Advisors, LLC164,748$1.1M
11UBS Group AG122,261$846K
12AMERIPRISE FINANCIAL INC120,156$831K
13ADAR1 Capital Management, LLC117,909$816K
14Tidal Investments LLC66,034$457K
15RENAISSANCE TECHNOLOGIES LLC66,000$457K